补骨脂定结构式
|
常用名 | 补骨脂定 | 英文名 | Psoralidin |
---|---|---|---|---|
CAS号 | 18642-23-4 | 分子量 | 336.338 | |
密度 | 1.4±0.1 g/cm3 | 沸点 | 458.8±34.0 °C at 760 mmHg | |
分子式 | C20H16O5 | 熔点 | 290-292° | |
MSDS | 中文版 美版 | 闪点 | 231.3±25.7 °C |
补骨脂定用途补骨脂定(Psoralidin)是从补骨脂中分离出的一种天然呋喃香豆素,具有抗癌活性。 |
中文名 | 补骨脂定 |
---|---|
英文名 | psoralidin |
中文别名 | 补骨脂定 | 补骨酯定 |
英文别名 | 更多 |
描述 | 补骨脂定(Psoralidin)是从补骨脂中分离出的一种天然呋喃香豆素,具有抗癌活性。 |
---|---|
相关类别 | |
参考文献 |
密度 | 1.4±0.1 g/cm3 |
---|---|
沸点 | 458.8±34.0 °C at 760 mmHg |
熔点 | 290-292° |
分子式 | C20H16O5 |
分子量 | 336.338 |
闪点 | 231.3±25.7 °C |
精确质量 | 336.099762 |
PSA | 83.81000 |
LogP | 5.03 |
外观性状 | white to beige |
蒸汽压 | 0.0±1.2 mmHg at 25°C |
折射率 | 1.689 |
储存条件 | ?20°C |
水溶解性 | DMSO: soluble5mg/mL, clear (warmed) |
危险品运输编码 | NONH for all modes of transport |
---|---|
海关编码 | 2932999099 |
补骨脂定上游产品 2 | |
---|---|
补骨脂定下游产品 0 |
海关编码 | 2932999099 |
---|---|
中文概述 | 2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
[Study on effect of psoralidin on anti-experimental postmenopausal osteoporosis and its mechanism].
Zhongguo Zhong Yao Za Zhi 38(11) , 1816-9, (2013) To observe the effect of psoralidine in rats with ovariectomy, and preliminarily study its mechanism.Sixty female Sprague-Dawley rats were divided into 5 groups: the sham operation group, the model gr... |
|
[Study on the chemical constituents of Psoralea corylifolia].
Zhong Yao Cai 34(8) , 1211-3, (2011) To study the chemical constituents of Psoralea corylifolia.Column chromatography was used in the isolation procedure. The structures of isolated compounds were elucidated by spectral data.Seven compou... |
|
Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation.
Biochem. Pharmacol. 82(5) , 524-34, (2011) Radiotherapy is the most significant non-surgical cure for the elimination of tumor, however it is restricted by two major problems: radioresistance and normal tissue damage. Efficiency improvement on... |
6H-Benzofuro[3,2-c][1]benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-buten-1-yl)- |
Psoralidin |
3,9-dihydroxy-2-(3-methylbut-2-enyl)-[1]benzofuro[3,2-c]chromen-6-one |
3,9-Dihydroxy-2-prenylcoumestan |
3,9-Dihydroxy-2-(3-methyl-2-buten-1-yl)-6H-[1]benzofuro[3,2-c]chromen-6-one |
3,9-Dihydroxy-2-(3-methyl-2-butenyl)-6H-benzofuro[3,2-c][1]benzopyran-6-one |
6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 3,9-dihydroxy-2-(3-methyl-2-butenyl)- |
3,9-Dihydroxy-2-(3-methyl-2-butenyl)-6H-benzofuro(3,2-c)(1)benzopyran-6-one |
6-(3-Methylbut-2-enyl)coumestrol |
3,9-Dihydroxy-2-(3-methylbut-2-en-1-yl)-6H-[1]benzofuro[3,2-c]chromen-6-one |